Wugen nabs $172M to advance memory NK cell platform

By The Science Advisory Board staff writers

Wugen announced it has raised $172 million to support further development of its NK cell platform and to continue ongoing trials for patients with severe acute myelogenous leukemia (AML).

In an ongoing phase I/II trial, WU-NK-101, the company's lead product, demonstrated an impressive complete response rate in relapsed/refractory AML, Wugen said. The company will also apply proceeds to advance its broader pipeline of next-generation products, including an allogeneic CD7-targeted CAR T cell therapy to treat T-cell leukemia and lymphoma.

The round of series B funding was co-led by Abingworth and Tybourne Capital Management.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?